Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 3/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3566620 | 0.99 | TSHR (0.50) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL9703312 | 0.84 | PREP (0.60) | TSHRL3MBTL1PREPGFERNPSR1 | |
| SCHEMBL9703304 | 0.84 | PREP (0.60) | TSHRL3MBTL1PREPGFERNPSR1 | |
| SCHEMBL24667753 | 0.82 | PREP (0.54) | PREPACE2ELANESMN1; SMN2 | |
| SCHEMBL28826460 | 0.82 | PREP (0.54) | PREPACE2ELANESMN1; SMN2 | |
| SCHEMBL2198876 | 0.82 | PREP (0.56) | TSHRL3MBTL1PREPACE2NPSR1 | |
| SCHEMBL2198909 | 0.82 | PREP (0.56) | TSHRL3MBTL1PREPACE2NPSR1 | |
| SCHEMBL2195118 | 0.82 | PREP (0.56) | TSHRL3MBTL1PREPACE2NPSR1 | |
| SCHEMBL1355706 | 0.81 | KLK7 (0.49) | TSHRL3MBTL1KDM4ELMNANPSR1 | |
| SCHEMBL1355709 | 0.81 | KLK7 (0.49) | TSHRL3MBTL1KDM4ELMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090318445-A1 | PDF INHIBITORS | NORVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-1973898-A1 | PDF INHIBITORS | Novartis AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007077186-A1 | PDF INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | TSHR 788/4885L3MBTL1 4819/4885KDM4E 1567/4885 |
| US-20090318445-A1 | PDF INHIBITORS | PDF, TIMP3, MMP2 | TSHR 4054/4885L3MBTL1 3997/4885KDM4E 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.